Key Points
- Insider David Kirn sold 58,333 shares of 4D Molecular Therapeutics at an average price of $12.92, generating $753,662; his remaining stake fell 7.6% to 709,153 shares. This follows several other sales since July.
- FDMT traded near $12.59, with a market capitalization of approximately $695 million. The company reported a quarterly loss of $1.04 per share, slightly worse than analysts’ expectations, while revenue of $3.78 million exceeded estimates.
- Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $28.90. Institutional investors own approximately 99.27% of the company’s outstanding shares.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider David Kirn sold 58,333 shares of the business's stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $12.92, for a total value of $753,662.36. Following the transaction, the insider owned 709,153 shares of the company's stock, valued at approximately $9,162,256.76. This represents a 7.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
David Kirn also recently made the following trade(s):
- On Monday, September 14th, David Kirn sold 58,333 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $13.90, for a total value of $810,828.70.
- On Monday, August 3rd, David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.05, for a total value of $124,770.75.
- On Friday, July 10th, David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.03, for a total value of $189,171.75.
- On Thursday, July 9th, David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.87, for a total value of $548,364.96.
4D Molecular Therapeutics Trading Up 0.2%
NASDAQ:FDMT opened at $12.59 on Thursday. The stock has a market cap of $695.47 million, a price-to-earnings ratio of -4.79 and a beta of 2.75. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03. 4D Molecular Therapeutics, Inc. has a 1 year low of $6.96 and a 1 year high of $16.93. The business has a fifty day moving average of $13.67 and a 200-day moving average of $11.36.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). The company had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. Equities analysts predict that 4D Molecular Therapeutics, Inc. will post -4.07 earnings per share for the current year.
Analysts Set New Price Targets
A number of research firms have commented on FDMT. Bank of America boosted their price target on shares of 4D Molecular Therapeutics from $29.00 to $33.00 and gave the stock a "buy" rating in a research report on Tuesday, September 29th. Chardan Capital lowered their price objective on shares of 4D Molecular Therapeutics from $26.00 to $25.00 and set a "buy" rating on the stock in a research note on Tuesday. HC Wainwright reissued a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. Weiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. Finally, B. Riley Financial reaffirmed a "buy" rating on shares of 4D Molecular Therapeutics in a research note on Monday, August 17th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $28.90.
View Our Latest Research Report on 4D Molecular Therapeutics
Institutional Investors Weigh In On 4D Molecular Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of FDMT. Opaleye Management Inc. boosted its position in shares of 4D Molecular Therapeutics by 197.8% during the 2nd quarter. Opaleye Management Inc. now owns 334,437 shares of the company's stock valued at $4,448,000 after purchasing an additional 222,146 shares in the last quarter. Engineers Gate Manager LP raised its holdings in shares of 4D Molecular Therapeutics by 132.0% in the 2nd quarter. Engineers Gate Manager LP now owns 68,206 shares of the company's stock worth $907,000 after purchasing an additional 38,806 shares in the last quarter. AXQ Capital LP acquired a new stake in 4D Molecular Therapeutics during the second quarter valued at approximately $186,000. Headlands Technologies LLC lifted its stake in 4D Molecular Therapeutics by 20.6% during the second quarter. Headlands Technologies LLC now owns 19,238 shares of the company's stock valued at $256,000 after purchasing an additional 3,282 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in 4D Molecular Therapeutics during the second quarter worth approximately $148,000. 99.27% of the stock is owned by institutional investors and hedge funds.
About 4D Molecular Therapeutics
(
Get Free Report)
4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs.
Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
